The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sanofi missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded, and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins improved, and net margins expanded.
Sanofi booked revenue of $11.05 billion. The nine analysts polled by S&P Capital IQ anticipated sales of $11.23 billion on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $10.47 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $2.03. The seven earnings estimates compiled by S&P Capital IQ predicted $2.02 per share on the same basis. GAAP EPS of $1.41 for Q4 were 213% higher than the prior-year quarter's $0.45 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 68.7%, 200 basis points worse than the prior-year quarter. Operating margin was 19.6%, 120 basis points better than the prior-year quarter. Net margin was 16.1%, 1,050 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $11.48 billion. On the bottom line, the average EPS estimate is $2.28.
Next year's average estimate for revenue is $46.34 billion. The average EPS estimate is $8.01.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sanofi is outperform, with an average price target of $77.37.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Sanofi the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Sanofi to My Watchlist.